Biomet Still Under Scrutiny For Overseas Bribery
This article was originally published in The Gray Sheet
Executive Summary
The company came under a Department of Justice inquiry for overseas bribery in 2012, and new allegations in 2014 have delayed a final close-out of the case. The formal agreements expired on March 26, but Biomet says it expects the investigation to continue.
You may also be interested in...
New Anti-Corruption Focus In Mexico May Include Medtech Scrutiny
Recently inaugurated Mexican President Andrés Manuel López Obrador campaigned on a promise to tackle the country’s corruption issues. Medtech Insight spoke to attorney Nicholas Berg, of Ropes & Gray, about what this may mean for device manufacturers doing business in Mexico.
Zimmer Biomet To Settle Overseas Bribery Charges With US DOJ
The orthopedic device company is set to pay $17.4m to the US Department of Justice and an additional $13m to the Securities and Exchange Commission to resolve allegations that Biomet didn’t stop corrupt acts in Brazil and Mexico even after a 2012 deferred prosecution agreement.
Manufacturer Settles Foreign Bribery Allegations Linked To Distributor 'Slush Fund'
Analogic Corp. and its subsidiary BK Medical APS are paying almost $15m to settle allegations that BK conspired with distributors to commit fraud overseas.